Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
Unicycive Therapeutics is a biotech company focused on treatments for chronic kidney disease and hyperphosphatemia. The company's stock is currently valued at $8 per share, with significant potential upside from its pipeline. Key risks include the acceptance of premium pricing by payers and the upcoming PDUFA date for its lead product.
- ▪Unicycive Therapeutics is valued at $8 per share, with $2 per share in cash.
- ▪The pipeline, primarily focused on OLC, is valued at $6 per share.
- ▪OLC targets hyperphosphatemia by reducing pill burden to improve patient adherence.
- ▪The PDUFA date for OLC is set for June 29, 2026.
- ▪Key risks include payer acceptance of premium pricing.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907351-unicycive-therapeutics-uncy-stock-catalyst-play-with-real-fundamental-upside"},"author":{"@type":"Person","name":"Logan…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
